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INTRODUCTION 
 One of the most dreaded complications of liver cirrhosis is oesophageal 
varices which is a result of portal hypertension. It carries a very high risk of 
mortality (20 to 35%). 
 The risk of developing oesophageal varices in cirrhotic patients over their 
life time amounts to about 5 to 15 percent per year and the rate of progression 
from small to large varices  amounts to 8 percent per year. Therefore early 
identification  and grading of varices remains the foremost step for risk 
assessment and thereby prevention of mortality. 
Upper gastrointestinal endoscopy remains the gold standard test for 
identification of varices. Patients who do not have varices with compensated 
cirrhosis should receive an endoscopic examination every 2–3 years. Those 
with small varices should receive an examination every 1–2 years. But it has the 
following disadsvantages: 
 invasive procedure that is unpleasant for patients 
 poses heavy burden on endoscopy units 
 detrimental effects of increase in risk of infections and bleeding 
 costly procedure. 
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Predicting the presence of oesophageal varices by non-invasive means 
increases compliance and this would restrict the performance of endoscopy on 
those patients with a high probability of having varices. 
Thus there is a need for some reliable non invasisive predictors for 
oesophageal varices which are cost effective , quick, simple and reproducible 
not adding burden to the patients. 
Many studies have been foccussed on such non -invasive predictors like 
platelet count , spleen size, portal vein diameter etc., and many models have 
been proposed. The sensitivity and specificity of  these models are highly 
variable and this study  focuses on a superior method of  variceal prediction 
based on right lobe liver diameter  albumin ratio. 
The right lobe liver diameter is a very easy parameter that can be 
measured simply as a part of ultrasound abdomen  and serum albumin levels are 
measured as routine biochemical investigation. Thus this method requires 
parameters which can be easily detected without any  additional efforts and 
thereby carries increased compliance. 
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AIMS &OBJECTIVES 
 
 To study the value of biochemical and ultra sonographic parameters in 
prediction of presence and size of oesophageal varices. 
 
 Right lobe of liver to albumin ratio can be used as a screening tool to 
suspect the presence of oesophageal varices. 
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REVIEW OF LITERATURE 
LIVER 
An accessory digestive gland that also serves many other vital functions 
.It is covered  by Glisson’s capsule. It weighs about 1.2 to 1.5 kg 
DEVELOPMENT 
At third week of gestation from foregut endodermal bud which divides 
into two-cranial and caudal. The cranial bud develops into liver and the hilar 
biliary tract. The caudal develops into gallbladder, cystic duct and ventral 
pancreas. 
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ANATOMY 
 Based on external appearance divided by falciform ligament into right 
and left lobes. But they are not of equal size. True right and left lobes are 
divided by cantlie line – passing through the bed of gall bladder and the notch 
of inferior vena cava. But these are not true functional lobes. 
COUINAUD SYSTEM 
This widely accepted system follows the distribution of portal and 
hepatic veins. 
 
HEPATIC ACINUS 
 It is the functional unit of liver, described by Kiernan. Hepatocytes lie in 
3 zones. The vulnerability of  hepatocytes to different perfusion and toxins 
contribute to the patchy nature of liver injury. 
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BLOODSUPPLY 
Dual blood  supply – portal vein 70% (formed by spleenic vein and 
superior mysentric vein) and hepatic artery 30%(from celiac trunk). 
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VENOUS DRAINAGE 
Hepatic sinusoids – interlobular veins – sublobular veins – hepatic veins- 
inferior vena cava. 
NERVE SUPPLY 
Hepatic nerve plexus(both sympathetic T7 to T10 and parasympathetic). 
LYMPHATICS 
 Terminate in caval, hepatic, coeliac  and few in mediastinal nodes. 
HISTOLOGY 
 
The zone 3 adjacent to terminal hepatic veins suffers most of the insults – 
viral , toxic or anoxic. In cirrhosis, the bridging necrosis may extend from zone 
1 to zone 3. The space of  Disse, contains the Stellate cells that are responsible 
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for the proliferation of fibroblasts during disease processs ultimately leading to 
cirrhosis. 
PORTOSYSTEMIC ANASTAMOSES 
Form important route of collateral circulation in portal obstruction due to 
portal hypertension. Various sites include : 
 Lower end of oesophagus (oesophageal varices) 
 Lower end of rectum (haemorrhoids) 
 Around umbilicus (caput medusa) 
 Bare area of liver. 
FUNCTIONS OF LIVER 
 Nutrient metabolism (carbohydrates, proteins and lipids). 
 Storage of iron, copper, vitamins A, D , B12. 
 Synthesis of proteins like albumin, coagulation factors, complement 
factors,  haptoglobin, ceruloplasmin, transferrin, protease inhibitors like 
alpha 1 antitrypsin 
 Excretion of  bile salts, bilirubin, drugs, cholesterol and phospholipids. 
 Immune functions by kupffer cells. (constitute the largest single mass of 
tissue resident macrophages in the body accounting for the phagocytic 
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activity eliminating bacteria, viruses, antigen antibody complexes and 
endotoxins) 
 Detoxification of variety of toxins. 
REGENERATIVE PROPERY OF LIVER 
Liver has immense potential of regeneration . Only about 20% of  
residual mass is enough for regeneration. Regeneration is induced by various 
signalling pathways including cytokines, growth factors, hormones and nuclear 
receptors. Regeneration is brought about mainly by hepatocytes. Cell 
proliferation is aided by angiogenesis. But  as the disease process still continues 
the irreversible changes progress and lead on to fibrosis resulting in cirrhotic 
liver. 
CIRRHOSIS 
It is defined as diffuse hepatic fibrosis and nodular formation altering the 
liver architecture. Chronic liver diseases usually alter the liver parenchyma 
resulting in liver cirrhosis. Usually after the hepatic injury there is tremendous 
increase in the extracellular matrix of liver especially type 1 and 3 collagen 
rather than type4. There is loss of endothelial  cell fenestrations thereby 
metabolic exchange between blood and livercells is affected leading to 
accumulation of type 1 collagen leading to fibrogenesis. The principal cell 
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involved in this entire process is the stellate cell present in the space of Disse. It 
is activated by kupffer cells and hepatocytes  in chronic liver diseases and it 
proliferates increasing the production of type 1 collagen leading to fibrosis. 
Cirrhosis is a histological diagnosis classified as micro nodular and 
macro nodular cirrhosis. Cirrhosis results in decreased liver function and 
increased resistance to flow of portal venous blood. Cirrhosis is generally 
irreversible in the late stages and liver transplantation is the only treatment 
option left in the advanced stage. Certain conditions causing cirrhosis responds 
to treatment of the underlying cause even resulting in reversal of the process in 
the early stages .This is seen especially in cirrhosis caused by hepatitis C, 
alcohol and obesity. 
Cirrhosis is the end stage of chronic injury leading to inflammation and 
destruction and regeneration of the hepatocytes, inflicted by various conditions 
ETIOLOGY 
The most common etiologies for development of cirrhosis is alcohol 
followed by viral hepatitis in developing countries like India. 
In developed countries the scenario changes due to the sedentary lifestyle 
thus the commonest etiology remains Nonalcoholic fatty liver disease (NASH- 
Non Alcoholic Steato Hepatitis) followed by viral cirrhosis (hepatitis C). 
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Cirrhosis is not a single step process. The main etiological agent with 
additional cofactors contribute to the pathological process and the rate of 
fibrotic changes increase with the persistence of the etiological agent. 
Cofactors include genetic factors,  age, sex, alcohol, iron intake, duration 
of disease, immunological factors. The various causes may also co interact. For 
example, the rate of cirrhotic changes is faster in a patient with viral hepatitis 
who drinks. Older the age, the fibrotic progression is rapid. 
Thus all changes revolve around a principal factor which interacts with 
various cofactors contributing to the cirrhosis. And also these changes have 
high individual variability based on patient’s susceptibility . 
Any condition leading to persistant or recurrent hepatocye death or 
prolonged biliary damage and obstruction or blockage of venous return from 
liver –all these above mentioned conditions trigger the cirrhotic changes 
defying the body’s hepato protective mechanisms. 
VARIOUS CAUSES  
 Toxic  
 Alcohol  
 Arsenic  
 Viral 
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 HBV 
  HCV  
 HDV  
 Autoimmune 
 Autoimmune hepatitis  
 PSC  
 PBC 
 Metabolic  
 α1-Antitrypsin deficiency  
 Wilson’s  
 Galactosemia 
 Glycogen storage disease 
  Hemochromatosis  
 NASH - Nonalcoholic fatty liver disease and 
steatohepatitis 
  Biliary  
 Atresia  
 Stone  
 Tumor 
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  Vascular  
 Budd-Chiari syndrome   
 Cardiac fibrosis  
 Genetic  
 CF  
 Lysosomal acid lipase deficiency 
  Iatrogenic  
 Biliary injury  
 Drugs: high-dose vitamin A, methotrexate 
Cryptogenic cirrhosis is a diagnosis of exclusion.  It is an end stage 
chronic liver disease in which the underlying etiology remains unknown even 
after extensive clinical, pathological and serological evaluations. The diagnosis 
should be finalised only after thorough assessment and evaluation for other 
causes. 
Cirrhosis is an irreversible process. The changes can be reversible only if 
the etiological agent is removed at very early stages. Cirrhosis progresses from 
a compensated state to a decompensated state. 
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CLINICAL MANIFESTATIONS 
Patient may be presenting with different scenarios. May be asymptomatic 
and incidentally be identified during checkup for unrelated causes  or present 
with  abnormal liver tests but clinically normal or may present with the 
complications at the very first visit . 
Clinically , cirrhosis may be 
 Compensated  or 
  Decompensated 
When complicated by one or more  features like –ascites, jaundice, 
hepatic encephalopathy, bleeding varices cirrhosis is said to be decompensated.  
First sign of decompensation is usually marked by ascites. 
In compensated cirrhosis all these features and any complication 
secondary to portal hypertension is absent. This clinical distinction  isvital 
because it delineates prognosis and management and most importantly a key 
role in deciding morbidity and mortality. 
Ten year survival rate is 50% for patients with compensated cirrhosis 
whereas decompensated patients have a survival rate of about 50% in 18 
months. When the inciting cause or the precipitating cause is removed, a 
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decompensated patient may become compensated  thus, the prognosis improves 
to a tremendous extent. 
FOUR CLINICAL STAGES OF CIRRHOSIS 
1.  Absence of ascites and varices 
2.  Varices without bleeding and absence of ascites 
3. Ascites with or without variceal bleeding 
4. Variceal bleeding with or without ascites. 
Stages 1 and 2-compensted cirrhosis: 3 and 4- decompensated cirrhosis. 
COMPENSATED CIRRHOSIS: 
The cirrhotic process of the liver is not severe enough to alter the 
function significantly at this stage. So the patients may be either asymptomatic 
or may be picked incidentally due to alteration in biochemical parameters or 
imaging studies. Patients may present with fatigue, flatulence ,dyspepsia, 
abdominal pain, anorexia, weight loss.  Palmar erythema, pedal edema, spider 
naevi on general examnation may provide clues suggestive of cirrhosis. On 
abdominal examination an epigastric mass which is the enlarged left lobe of the 
liver and mild splenomegaly may be the findings.   In this group, biochemical 
tests are usually within normal limits. Mildly elevated transaminase may be 
some times the only finding. Confirmation can be attributed only by liver 
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imaging or liver biopsy (the gold standard test). Decompensation in 
compensated cirrhosis may be precipitated by factors like bacterial infection, 
trauma, or medications or surgery . 
DECOMPENSATED CIRRHOSIS: 
When the patients present with ascites, jaundice, altered sensorium, 
bleeding manifestations the cirrhosis is said to be decompensated. 
SYMPTOMS 
Patient may complain jaundice, pedal edema, abdominal distension, 
melena, hematemesis suggestive of upper GI bleed , pruritus, altered sensorium 
which may present either as altered sleep pattern or florid confusion and coma 
suggestive of  hepatic encephalopathy. 
Menstrual irregularities are common due to anovulation in women 
.Hypogonadism in the form of impotence, loss of sexual drive, testicular 
atrophy and infertility may be the presenting complaints in men. 
GENERAL EXAMINATION 
Decreasing blood pressure - with progression of cirrhosis, mean arterial 
pressure often decreases. Hypertensive patients may become normotensive. 
Patient has an ill look with cirrhotic facies. Patients may be febrile (37.5 -
38 C) which is due to bacteremia due to gram negative organisms. It may also 
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be due to ongoing hepatocyte necrosis, development of hepatocellular 
carcinoma. 
From head to foot one or more signs of liver cell failure can be identified 
as follows: 
 Head :Aloepecia, madarosis 
 Face: bilateral parotid enlargement 
 Eyes :  
 Jaundice (because of functional impairment due to 
hepatocyte destruction  thathas exceeded the process of 
regeneration. Depth of jaundice correlates with degree of 
decompensation. 
 Bitot spot 
 Subconjunctivalhemorrhage, kf ring 
 Oral cavity : Fetor hepaticus -  the breath of the cirrhosis patients 
that has a sweet pungent nature because of presence of 
mercaptans. 
 Loss of axillary hair 
 Skin findings: 
 the presence of bronze pigmentation of the skin throws 
light on the etiology as it occurs in hemochromatosis. 
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 Hands:  
 Palmar erythema ( warm and red palms especially over the 
thenar eminence, hypothenar eminence and the pulp of the 
finger) 
 Dupytrens contracture: thickened palmar fascia resulting 
from unorganized proliferation of the fibroblasts. 
 Clubbing : pan digitally especially with development of 
hepato pulmonary syndrome or in cystic fibrosis 
.Hypertrophic osteoarthropathy has also been observed 
 Terry nails:Leukonychia (related to hypoalbuminemia) 
 Asterixis / flapping tremors. 
 Chest wall 
 Presence of spider naevi (arterial spiders/ vascular spiders / 
spider telangiectasia/ spider angioma). Seen along 
distribution of  drainage areas of superior vena cava. New 
spiders may appear as liver function worsens, frequently 
associated with alcoholic cirrhosis . It is a normal finding 
in pregnancy .Multiple spiders and clubbing should arise 
the suspicion of  hepato pulmonary syndrome 
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 Painless gyenacomastia in males seen along with other 
features of feminization like change in the male pattern of 
pubic hair, loss of axillary hair and chest hair because the 
androstenedione that is synthesized by the adrenals gets 
aromatized in to estrone and finally in to estradiol in the 
adipose tissue. 
 Breast atrophy in females. 
Hyperoestrogenic state is the mechanism  behind both arterial spiders and 
palmar erythema . Due to liver failure, estrogen cannot be  inactivated in the 
liver. Serum free testosterone is reduced even though serum estradiol level is 
normal .The high estradiol/free testosterone ratio may be attributed to these 
findings. 
 Abdominal findings 
 Ascites — excessive collection of peritoneal fluid .In 
massive ascites fluid thrill may be present and  in moderate 
ascites shifting dullness is present.  
 Liver  -On palpation, liver size is normally reduced; 
consistency is firm and nodular. Palpable liver in cirrhosis should 
arise suspicion of  transformation into hepatocellular carcinoma, 
primary biliary cirrhosis, cardiac cirrhosis, alpha 1 antitrypsin 
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deficiency, Indian childhood cirrhosis, hemochromatosis, Budd 
Chiari syndrome. The  shape, consistency, tenderness should be  
better appreciated on palpation as the estimation of liver size 
correlates less accurately with imaging studies. 
 Splenomegaly - Splenomegaly in cirrhosis results 
from portal hypertension due to congestion. But correlation 
between splenic size and portal pressure is poor . 
 Umbilical hernia 
 Caput medusa –The  appearance resembles the head 
(caput) of the mythical Gorgon Medusa and so named  caput 
medusae. Due to portal hypertension the porto systemic 
anastamoses open up. The mechanism being-  the portal venous 
blood that gets carried through the peri umbilical veins in to the 
umbilical vein which becomes patent in cirrhosis .Then  the blood 
drains into the upper and lower abdominal veins that end up in 
systemic circulation resulting in the engorgement and prominence 
of the veins around umbilicus. Thereby the  portal blood gets 
shunted to systemic circulation.  
 Dilated abdominal veins: they also develop in SVC 
obstruction and IVC obstruction  and should be differentiated 
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from dilated veins due to cirrhosis. To know the cause of 
obstruction assessment of direction of flow is vital. In cirrhosis 
the flow of the blood is away from the umbilicus. In IVC 
obstruction the flow is below upwards. The test may be 
misleading some times since these veins in both conditions may 
lack valves, the flow may be bidirectional. The dilated veins due 
to IVC obstruction are more commonly seen in the back and loin. 
 Genitourinary findings  
 Testicular atrophy  
 Scrotal edema 
 Loss of pubic hair 
 Bilateral pitting pedal edema 
ENDOCRINE CHANGES 
 Hyperglycemia (in 80% patients) 
 Hypothalamo pituitary dysfunction 
 Hypogonadism 
 Altered metabolism of hormones 
 Muscle cramps due to increased RAS activity 
Drug metabolism is also affected therefore drugs are to be 
prescribed with extreme degree of caution.  
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ABDOMINAL PAIN IN ALCOHOLIC CIRRHOTIC PATIENTS 
Peptic ulcers occur in about 11% of cirrhosis patients. Duodenal ulcers 
are more common because colonization by helicobacter pylori is higher in 
cirrhosis when compared to normal population. 
Alcoholics are more prone for chronic pancreatitis. Hence these two 
conditions must be ruled out in the view of abdominal pain in alcoholic 
cirrhosis. 
INVESTIGATIONS 
Liver function test  
 Bilirubin - the bilirubin levels are usually normal in compensated 
stage of cirrhosis . Increasing levels of bilirubin marked 
decompensation . It is one of the prognostic indicators used in 
Child Pugh score. 
 Aminotransferases -In cirrhosis patients the enzymes can be 
moderately elevated  or within normal values .In chronic hepatitis, 
initially ALT is increased more than AST. Then as hepatitis 
progresses to cirrhosis ,AST becomes more elevated than ALT.           
The  ratio of AST to ALT is reversed from <1 to greater than 1 . 
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  Alkaline phosphatase — It is elevated 2 to 3 times  in cirrhosis. 
Primary biliary cirrhosis or sclerosing cholangitis should be 
considered as the etiology  if elevated more than that. 
 Gamma- glutamyltransferase– GGT is present in the microsomes 
and is induced due to alcohol intake. GGT and alkaline 
phosphatase are usually proportionately elevated 
Disproportionately high levels of GGT will be seen in alcoholic 
liver disease.  
 Serum electrolytes – In ascites, hyponatremia occurs. If severe 
indicates the  worsening  of cirrhosis. 
 Albumin — Albumin is synthesized exclusively in the liver about 
15 g/day. With worsening cirrhosis albumin levels also fall. It is 
also one of the prognostic indicators for survival in child scoring 
system. 
It is the most important plasma protein which accounts for 75% of 
the plasma colloid oncotic pressure and is synthesized by 
hepatocytes.   In an average adult about 300 to 500 g of albumin 
distributed in body fluids. The liver can double the rate of 
synthesis in the setting of rapid albumin loss or a dilutional 
decrease in the serum albumin concentration. 
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 The half-life of albumin is 14 to 21 days. This  long half-life of 
albumin in serum accounts for its unreliability as a marker of 
hepatic synthetic function in acute liver injury. Changes in 
nutritional status, osmotic pressure, systemic inflammation, and 
hormone levels regulate albumin synthesis. The differential 
diagnosis of serum hypoalbuminemia, in addition to 
hepatocellular dysfunction, includes malnutrition, excessive loss 
from protein-losing enteropathy or nephrotic syndrome, chronic 
systemic inflammatory conditions, and hormonal imbalances.  
Serum albumin levels less than 3 g/dL in a patient with features of 
hepatitis should arise suspicion of chronic process.  
 Thus serum albumin is an excellent marker of hepatic synthetic 
function in patients with chronic liver disease and cirrhosis 
Albumin globulin ratio- A/G reversal is seen in cirrhosis. In cirrhosis, the 
globulin levels are high because of shunting of bacterial antigens in the portal 
venous blood which are normally filtered by the liver in to systemic circulation. 
This leads to production of immunoglobulins. But marked elevations of IgG 
points towards the presence of autoimmune hepatitis. 
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 Prothrombin time — a measure of the extrinsic 
coagulation pathway, is a marker for the synthetic function 
of the liver because most of the coagulation factors are 
synthesized in liver. Thereby coagulopathy worsens as 
cirrhosis progresses. 
 Hematologic abnormalities -
Thrombocytopenia, anemia and leucopenia manifest.  
 Among them the earliest abnormality to occur is 
thrombocytopenia and it is a potential  marker for the 
development of portal hypertension. Platelet count 
does not fall below 50,000. Bleeding can get 
aggravated in the presence of coagulopathy. 
  Pancytopenia – it can even be the presenting feature 
in asymptomatic compensated cirrhosis due to 
sequestration of the cells in the enlarged spleen.  
 Anemia- Mainly because of upper GI bleed in 
cirrhosis. It can also be present as a result of direct 
suppression of bone marrow by alcohol, sequestration 
and hemolysis, folate deficiency. 
 Viral markers -  HBsAg, HCV, HIV 
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IMAGING STUDIES: 
NON INVASIVE 
 Ultrasonography —  Anon-invasive investigation to diagnose cirrhosis. 
Various parameters like the liver size, the nodularity, the portal vein 
diameter, presence of ascites and splenomegaly can be assessed. Also 
the presence HCC, portal vein thrombosis can be made out. 
 Doppler studies  can also be done. This checks the direction of blood 
flow in the portal vein thereby aiding in the diagnosis of portal 
hypertension.  
 CT- useful only when investigating liver malignancy or secondaries or 
pancreatic pathology. Not the first choice in the diagnosis of cirrhosis. 
 MRI- it is very useful in hemochromatosis to reveal iron overload.  
 MRA - determines portal vein flow and dynamics. 
 
INVASIVE TECHNIQUES 
Liver biopsy: 
 It is the gold standard investigation for diagnosing cirrhosis . Nowadays 
liver biopsy is not frequently used to diagnose cirrhosis. 
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Performing liver biopsy may be required in special circumstances such as 
for demonstrating the underlying metabolic cause of cirrhosis such as NASH, 
Wilson disease, hemochromatosis and alpha 1 antitrypsin deficiency. 
Upper GI endoscopy 
Gold standard for variceal detection 
PROGNOSIS 
Child-Turcotte-Pugh Score (CTP):  
It is a simple scoring system, for predicting the prognosis from the major 
complications of the cirrhosis patients which is widely in use in clinical 
practice. Though practically difficult, this score has reasonable accuracy. 
This is used in the stratification of patients in to risk groups before taking 
them up for porto systemic shunt surgeries and to prioritize the patients to be 
taken up for liver transplantation (Child Pugh class B). Now this system has 
been replaced by MELD score for selection of patients for liver transplantation. 
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“Child-Turcofte-Pugh Classification for Severity of Cirrhosis” 
 “Points* 
1 2 3 
Encephalopathy None Grade 1-2 
(or precipitant induced) 
Grade 3-4 
(or chronic) 
Ascites None Mild to moderate 
(diuretic responsive) 
Severe 
(diuretic refractory) 
 
Bilirubin (mg/dL) <2 2 - 3 >3 
Albumin (gfdL) >3.5 2.8 – 3.5 <2.8 
INR <1.7 1.7 – 2.3 >2.3 
Class A- 5 to 6 points (least severe liver disease) 
Class B -7 to 9 points (moderately severe liver disease) 
Class C -10 to 15 points (most severe liver disease)” 
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Model for End-stage Liver Disease (MELD) score  is derived 
methodologically in order to prognosticate the patients with cirrhosis and portal 
hypertension .It is calculated based on three noninvasively obtained variables: 
serum bilirubin, serum creatinine 
”MELD Score 
MELD = 3.78 x Iog serum bilirubin (mg/dL) + 
11.20 X 109e INR + 
9.57 x loge serum creatinine (mg/dL) + 
6.43 (constant for liver disease etiology) 
NOTES 
• If the patient has been dialyzed twice within the Iast 7days,then the value 
for serum creatinine used should  be 4.0 
• Any vaIue less than one is given a value of 1 (ie. if bilirubin is 0.8,a value 
of 1.0 is used) to prevent the occurrence of scores below 0 and INR” 
 
Patient with a score > 10 is to be considered for liver transplantation.  
Based on this the patients with cirrhosis are given priority for liver 
transplantation. The advantage is that it is completely objective for assessment 
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of severity of the disease and there is no inter observer variation. Grading is 
more precise as it has wider range of values. 
COMPLICATIONS OF CIRRHOSIS 
Complications occur as a result of either the decreased synthetic, 
excretory, metabolic functions of the liver with the progression of cirrhosis 
attributed to the development of portal hypertension 
Various complications include, 
 Portal hypertension 
 Upper GI bleed (Gastroesophageal varices) 
 Ascites 
 Splenomegaly, hypersplenism  
 Spontaneous bacterial peritonitis  
 Coagulopathy 
 Hepatic encephalopathy  
 Hepato renal syndrome 
 Hepato pulmonary syndrome 
 Porto pulmonary hypertension 
 Bone disease( osteopenia, osteoporosis, osteomalacia) 
 Haematological abnormalities (anaemia, neutropenia, thrombocytopenia) 
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 Malnutrition  
 Infections  
 Portal gastropathy 
 Cirrhotic cardiomyopathy 
PORTAL HYPERTENSION: 
The normal hepatic venous pressure gradient (HVPG)  is 5 to 6 mm Hg 
Portal hypertension is defined as “the elevation of the hepatic venous pressure 
gradient (HVPG) to >5 mmHg”. 
CAUSES 
 pre-hepatic 
 intra-hepatic causes 
 post hepatic. 
Pre-hepatic causes are those that results in development of sinistral 
hypertension or left sided portal hypertension. It includes portal vein thrombosis 
and splenic vein thrombosis. Also Portal vein thrombosis can occur secondary 
to pancreatitis, abdominal trauma and infection or hematological causes such as 
essential thrombocytosis,  polycvthemia   vera, Protein C and S deficiency 
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Intra-hepatic causes may be pre sinusoidal, sinusoidal or post sinusoidal. 
Pre – sinusoidal causes include schistosomiasis and congenital portal fibrosis . 
Cirrhosis causes sinusoidal form of portal hypertension. Post sinusoidal causes 
includes veno-occlusive disease  
Post hepatic causes  affect the hepatic veins and venous drainage in to the 
heart. Budd Chiari syndrome veno occlusive disease, constrictive pericarditis, 
chronic right sided congestion, restrictive cardiomyopathy are some conditions 
causing post sinusoidal portal hypertension. 
PATHOGENESIS  
Portal hypertension results due to two simultaneous processes : 
 Increased resistance to the flow of the portal blood due to the 
altered liver architecture due to fibrosis and regenerating nodules 
 Increased blood flow secondary to splanchnic vasodilatation. 
The development of portal hypertension may be revealed by the presence 
of thrombocytopenia, appearance of an enlarged spleen, encephalopathy, 
development of ascites and esophageal varices with or without bleeding in 
patients with liver cirrhosis 
60% of cirrhotics develop significant portal hypertension leading to 
complications. The primary complications of portal hypertension include 
ascites, bleeding varices and hypersplenism. 
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GASTRO OESOPHAGEAL VARICES 
Among those affected one third of the patients with cirrhosis have gastric 
and oesophageal varices. So mandatory screening of all patients with 
established cirrhosis for the presence of varices using upper GI endoscopy is 
necessary. 
Several factors like the varices size, severity of cirrhosis, tense ascites, 
and increased wedged hepatic vein pressure together govern the development of 
varices 
Diagnosis is made by upper gastro oesophageal endoscopy which is an 
invasive procedure. 
ENDOSCOPIC GRADING OF ESOPHAGEAL VARICES 
GRADE FINDING 
0 Abscence of varices. Repeat endoscopy in 2-3 years. 
1 Microcapillaries present. Repeat endoscopy in 1-2 years. 
2 1-2 small varices, no hemmorhage 
3 Medium sized varices 
4 Large sized varices 
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                  CT or MRI abdomen can be performed in doubtful cases or 
interventional radiological procedure to determine the free and wed hepatic vein 
pressure and the gradient between the two can be found out .The normal value 
is 5 mm Hg and if more than 12 mm Hg it signifies increased risk of bleeding. 
                Acute therapy is given to arrest the bleed and then followed by 
prophylaxis against repeated bleeding.  Administration of  intravenous fluids 
and blood products and use of octreotide at a rate of 50-100 mic/hour 
immediately to arrest bleeding. Then is endoscopic variceal band ligation done 
to obliterate the varices. In case of failure, TIPS can be tried. For prophylaxis 
non selective beta-blockers can be used.  
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ASCITES: 
It is defines as excessive accumulation of peritoneal fluid.  In cirrhosis it 
may be de novo or may be due to spontaneous bacterial peritonitis or 
development of malignancy. 
PATHOGENESIS 
Mechanisms that  contribute to the occurrence of ascites in cirrhosis with 
portal hypertension include: 
Increase in the intrahepatic resistance causes increase in portal pressure . 
This is accompanied by vasodilatation in splanchnic arterial system due to 
release of vasodilatory substances such as nitric oxide which results  in 
increased portal inflow. All these ultimately leads to increase in the  production 
of splanchnic lymph. 
The intravascular volume depletion occuring due to splanchnic 
vasodilatation results in under filling in other vascular beds  leading  to 
increased activity of the renin angiotensin system .Finally there is increase in  
release of aldosterone leading to sodium and water retention and thus peripheral 
edema and ascites. This is also aided by the decreased oncotic pressure due to 
hypoalbuminemia. 
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Ascites may lead to hepatic hydrothorax also due to the diaphragmatic 
pores . Most common being right sided pleual effusion. 
Ascitic fluid tapping is to be done and ascitic fluid analysis must be 
interpreted includingproteins, cell count and sugar levels. In cirrhotic patients, 
the ascitic protein content is very low, less than 1.1 g/dl which is an indirect 
indicator for increased risk of spontaneous bacterial peritonitis.Ascitic fluid 
polymorphonuclear cell count, of more than 250 cells/mic L indicates the 
presence of infection RBCs in ascetic fluid indicates the presence of 
malignancy, omentalvarices or traumatic tap. SAAG ratio (‘serum to ascites 
albumin gradient’) is a recent parameter for assessment of the nature of ascitic 
fluid. If  SAAG ratio < 1.1 g/dl infection or malignancy has to be ruled out.  If  
it is>1.1 g/dl  it denotes that ascites is due to portal hypertension. 
Management in case of mild ascites is attained by salt restriction < 2 g 
/day  and life style modifications. 
Moderate ascites is managed by pharmacological means by diuretics.  
From  a starting dose of 40 mg frusemide and 100 mg spirinolactone dose can 
be escalated up to 400-600 mg spirinolactone and furosemide  upto 160 mg. 
Ascites is said to be refractory if it is still present with these dosage of diuretics 
and a strict salt restricted diet. Alpha antagonists like clonidine, midodrine can 
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be tried. Resistant ascites has a bad prognosis with survival rates not more than 
50% at the end of two years. 
For repeated large volume refractory ascites therapeutic tapping, 
intravenous albumin infusion and TIPS are the choice. 
SPLEENOMEGALY 
Moderate  spleenomegaly develops in cirrhosis due to congestion from 
increased portal pressure. Sometimes thrombocytopenia due to hyperspleenism 
may be the first presentation of portal hypertension even before ascites may 
develop. 
SPONTANEOUS BACTERIAL PERITONITIS: 
Occurs spontaneously  due to infection of the ascitic fluid without an 
intraabdominal source.  SBP is usually monobacterial, if polymicrobial - 
perforation of viscus is to be considered.  Mechanism behind SBP is not very 
clear .The probable mechanism may be bacterial translocation from the 
intestines in to the mesenteric lymph nodes followed by bacteremia and seeding 
of ascites. 
The commonest organism cultured is Escherichia coli. Other gram 
positive bacteria causing SBP include, Streptococcus viridians, enterococcus 
and staphylococcus aureus. Symptoms include fever, sudden increase in ascites, 
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abdominal pain and altered sensorium. Treatment is with second generation 
cephalosporins (1 g iv bd).   High risk patients are those with prior history of 
SBP, very low proteins in ascitic fluid and in patients with upper GI bleeding. 
They are provided with once weekly  as prophylaxis. 
ABNORMALITIES OF COAGULATION: 
Coagulopathy  results  due to the decreased production of clotting factors 
and impaired clearance of anticoagulants. Thrombocytopenia as a result of 
hypersplenism due to portal hypertension also contributes to bleeding 
manifestation.. Platelet function is also abnormal (thrombasthenia) is also 
evident  apart from reduction in its number. 
HEPATIC ENCEPHALOPATHY: 
More common in patients with cirrhosis. It is defined as a complex 
syndrome of neuropsychiatric manifestations with disturbances in conscious 
level and personality changes which fluctuate from day to day occurring either 
in chronic liver disease or fulminant hepatic failure. Also called as porto 
systemic encephalopathy. 
PATHOGENESIS 
Due to the deficient detoxifying ability of  cirrhosed liver,  there occurs 
accumulation of gut-derived neurotoxins  in the systemic circulation These 
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neurotoxins mainly include ammonia, levels of which when  elevated in CLD 
patients  attribute to the symptoms in hepatic encephalopathy. Other compounds 
like mercaptans, GABA are also elevated that contribute to encephalopathy. 
Factors precipitating hepatic encephalopathy include constipation, SBP, 
hypokalemia, dehydration, UGI bleed, increased dietary protein load , overt use 
of diuretics and inadventparacentesis. Avoidance of these precipitating factors 
is the foremost step to be done in management process. 
Earliest symptom is the alteration of sleep pattern.other features include 
behavioural alterations, loss of consciousness, slurring of speech , rarely 
convulsions. 
Earliest sign that can be elicited is constructional apraxia. Others include 
flapping tremors( also called -Asterixis .It is elicited by having the patients 
extend their arms and bending their wrists backward. In this maneuver, patients 
who are encephalopathic may have a “liver flap”-i.e. a sudden jerky  forward 
movement of the wrist every 5 to 10 seconds), hyperreflexia, bilateral plantar 
extensor. 
The EEG shows slowing of alpha waves initially later delta waves 
appear. 
The first step in management is to avoid the precipitating factors. 
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Ryles tube aspiration  to check any ongoing GI bleed  and patients to be  
appropriately hydrated. Correction of  electrolyte abnormalities. Vegetable 
proteins are preferred over animal proteins. Bowel wash to be given. 
Lactulose 15 to 20 ml an osmotic cathertic a non-absorbable 
disaccharide, converts ammonia into ammonium by enhancing acidic medium 
and prevents the diffusion of ammonia produced in the gut in to portal system. 
It also alters the gut flora in such a way that they favourable. .Their use became 
limited due to side effect such as ototoxicity and peripheral neuropathy. The gut 
antibiotic of choice now is Rifaximin at a dosage of 550 mg twice daily. Zinc 
supplement can also be tried. 
HEPATORENAL SYNDROME: 
There is marked reduction in glomerular filtration rate and renal plasma 
flow (RPF), without any other contributing cause to renal failure. This is very 
typical of  hepato renal syndrome. 
HRS is attributed to the reversible functional renal impairment which 
develops in patients with end stage liver cirrhosis or those with acute fulminant 
liver failure without any anatomical alteration. 
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PATHOGENESIS 
It occurs in the end stage of liver cirrhosis.  The peculiarity is that, the 
function of the renal tubules is normal. There is no proteinuria or abnormal 
histology in the kidneys. 
HRS is attributed to severe vasoconstriction in the renal vascular bed. 
There is paradoxical peripheral arterial vasodilation. The development of HRS 
is the end result of the interaction between multiple mechanisms. 
 Splanchnic vasodilation associated with hyper dynamic circulation with 
consequent renal vasoconstriction. 
 There is activation of renal sympathetic nervous system. 
  Cardiac dysfunction that may result in decreased renal gfr. 
  Different vasoactive mediators and cytokines act over renal circulation. 
 All ultimately leads to peripheral arterial vasodilation. 
TYPES 
 Two types of HRS exists 
 Type 1 HRS 
It is defined as the “rapidly progressive which is of acute onset oliguric 
renal failure unresponsive to volume expansion with the doubling of  serum 
creatinine value to more than 2.5 mg/dl within 2 weeks duration”. 
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Diagnosis of type 1 HRS should be made only when it fulfils the criteria 
defining acute kidney injury. There should be an abrupt increase in serum 
creatinine more than or equal to 0.3 mg/dl or an increase of more than 1.5 times 
from the baseline. This ensures there is no unnecessary delaying of treatment as 
baseline creatinine is a predictor of HRS reversal with vasoconstrictors. 
 Type 2 HRS 
It manifests clinically as refractory ascites. It has a slower progression 
and the cut off of serum creatinine is 1.5 mg/dl. 
In type 1 HRS, a precipitating factor is identified frequently but there are 
no such factors involved in development of type 2 HRS.  In type 2 HRS there is 
gradual progression of the mechanisms responsible for development  of  HRS 
whereas in type 1 HRS,  worsening of the kidney function is sudden due to 
inability of the compensatory mechanisms to maintain the perfusion in the renal 
arteries 
There is increased production of certain vasodilating factors such as nitric 
oxide, in patients with cirrhosis and portal hypertension and to a lesser extent in 
systemic circulation .This leads to both splanchnic and systemic vasodilatation. 
Thus there is splanchnic blood pooling as there is also increased resistance to 
the flow of the portal blood through the fibrosed  liver. 
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As a result of all above mechanisms, the effective circulating 
intravascular volume decreases. Stimulation of carotid baroreceptors thereby 
increasing the activity of sympathetic nervous system (SNS).  Also there is 
decrease in the effective volume of renal blood flow stimulating the renin 
angiotensin aldosterone system (RAAS). There is decreased peripheral vascular 
resistance and renal vasoconstriction resulting in a hyper dynamic circulation. 
As the cirrhosis progresses, this process becomes a vicious cycle. There 
by further increase in splanchnic vasodilatation, worsening the renal 
vasoconstriction. 
Effect of stimulation of the Renal SNS: 
Reflexes such as hepato renal reflex determines the renal 
vasoconstriction  in response to increased pressure in hepatic sinusoids. Renal 
sympathetic system mediates this process. 
The following are the problems with assay , that makes it difficult as a 
diagnostic tool: 
 It  needs further standardization. 
  The levels are highly variable as they may be altered in infection and by 
drugs such as steroids ,ACE inhibitors and calcineurin inhibitors. 
 Also  assay is a costlier technique. 
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Use of Cystatin C is still not validated though it is a marker for fibrosis 
progression in liver cirrhosis because this could represent a possible bias during 
the process of interpretation of the results. 
Renal Doppler Ultrasonography: 
The major pathology behind all these is renal vasoconstriction. 
Assesment of this renal vasoconstriction is possible by using Doppler 
ultrasound of the renal arteries through an  index called renal resistive index 
(RI). There have been numerous studies  conducted to elicit the use of renal 
resistive index in cirrhosis patients thereby  identifying early renal dysfunction. 
It is determined using the formula 
‘Renal Resistive Index’ 
“RI” = “Peak systolic frequency shift - Lowest diastolic frequency shift” 
                                              “Peak systolic frequency shift” 
A high RI value (>0.7) has been documented in cirrhotic patients even in 
whom RFT is norm al.  Thus RI is  increased in cirrhosis when compared to the 
normal population. 
Future development of HRS in patients with cirrhosis can be predicted to 
some extent by early detection of renal vasoconstriction through Doppler 
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ultrasound. “HRS develops in 26% of patients with elevated resistive indices 
compared with 1% of those with normal indices (P < 0.001) and the probability 
that patients with high RI would subsequently develop HRS is 55%.” 
A gradient decreasing from the hilum towards the outer cortex is 
exhibited normally by RI.  In cirrhotic patients with diuretic responsive ascites 
this gradient is well maintained. Whereas as the severity increases and in 
cirrhotic patients with refractory ascites this gradient is lost. Renal cortex 
vasoconstriction is suspected when RI at the level of the cortex measured in 
interlobular arteries is high.  This happens  earlier even before serum creatinine 
raises . In cirrhotic patients an increased RI in spite of normal values of serum 
creatinine should raise the suspicion that they are at a greater risk for 
development of renal dysfunction and  also elevation of serum creatinine. 
Liver transplantation decreases the RI. Thus renal RI assessment using 
Doppler ultrasound can be used as an early marker for renal impairment in 
cirrhosis patients. The disadvantage is that “raised RI does not differentiate 
whether the cause of renal dysfunction is due to vasoconstriction alone or if it is 
associated with intrinsic kidney damage.” 
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HEPATO PULMONARY SYNDROME 
It is defined as “Clinical disorder associated with advanced liver disease, 
pulmonary vascular dilatation and a defect in oxygenation in the absence of 
detectable primary cardiopulmonary disease” 
Among the patients with decompensated cirrhosis almost about 1/3rd have 
reduced arterial oxygen saturation. They may even be cyanosed. “Po2 is < 
80mmHg (10.6 kPa) and the alveolar – arterial oxygen gradient is > 15 mmHg 
(2 kPa) breathing room air”. 
                 It is characterised by: 
 Orthodeoxia (fall in the arterial Po2 in the upright position. 
  Platypnoea (shortness of breath relieved by lying down).  
There is intrapulmonary shunting due to marked dilatation of precapillary 
and capillary vessels leading to the diffusion limitation of capillary oxygenation 
and ventilation – perfusion mismatch. 
The probable vasoactive substances that could induce pulmonary 
vasodilatation in cirrhosis include NO, endothelin - 1 and tumour necrosis 
factor α. HPS leads to poorer quality of life and the mortality rate is twice that 
of cirrhotic patients without HPS 
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DIAGNOSIS 
Diagnosis is by demonstration of pulmonary vasodilatation and an 
increased alveolar – arterial oxygen gradient on breathing room air. The 
demonstration of abnormal passage of microbubbles through the pulmonary 
circulation into the left side of the lung can be made by contrast - enhanced 
echocardiograph . 
Other less sensitive techniques include Technetium 99m ( 99m Tc)  
macroaggregated albumin lung scanning . Pulmonary angiography shows large 
pulmonary arteriovenous shunts.  Exclusion of  intracardiac shunts is done 
bythe transoesophageal contrast echocardiography. 
No effective pharmacological therapy has been found. In some patients, 
Transjugular intrahepatic portosystemic shunt (TIPS) has improved arterial 
oxygen saturation . But the results are unpredictable. 
Currently, the only effective treatment is liver transplantation.  Indication 
for liver transplant is progressive and severe hypoxaemia.  However hypoxemia 
following transplantation may take weeks or months to resolve. When 
pulmonary arteriovenous shunts are large  reversal is not always possible. So 
coil embolotherapy , should precede transplant. 
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PORTOPULMONARY HYPERTENSION 
It is defined as, “portal hypertension and a mean pulmonary artery 
pressure above 25 mmHg and pulmonary vascular resistance above 240 
dynes/s/cm 5 , in the absence of other diseases associated with pulmonary 
hypertension” and can occur with hepatic or prehepatic portal hypertension. 
About 5% of transplant candidates have portopulmonary hypertension. 
Patients mostly complain of non - specific chest discomfort or dyspnoea on 
exertion. A  right ventricular heave or a loud second heart sound is the usual 
finding. The pulmonary arteries show dilatation and thickening of the wall and, 
rarely, thrombi. There is plexogenic pulmonary arteriopathy. Significant 
pulmonary hypertension (mean pulmonary artery pressure > 35 mmHg) can 
result in perioperative deaths from acute right ventricular failure. Thus it is  a 
relative contraindication to liver transplant.  So all liver transplant candidates 
should be screened using echocardiography.Treatment is with prolonged oral  
sildenafil .  Response is good with a reduction in pulmonary vascular resistance 
and pulmonary artery.  Bosentan is an alternative treatment but  the limitation is 
that it is not recommended for patients with moderate to severe hepatic 
impairment. 
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BONE DISEASE IN CIRRHOSIS: 
Vitamin D malabsorption due to cholestasis is responsible for 
osteomalacia. Ultimately this leads to increase in the rate of bone 
resorptionwhich exceeds that of new bone formation in patients with cirrhosis, 
resulting in bone loss. 
For the determination of osteoporosis and osteopenia , Dual x-ray 
absorptiometry (DEXA) is a useful. Bisphosphonates are the treatment of 
choice as they are effective at inhibiting resorption of bone and highly 
efficacious in the treatment of osteoporosis. 
INFECTIONS 
In cirrhotic patients, bacteraemia, pneumonia and urinary tract infections 
are common. This is because of the bacteriologically sterile  nature of  human 
liver  and the portal venous blood  rarely contains any  organisms. 
But in the cirrhotic patients, the intestinal bacteria could reach the general 
circulation either by passing through a faulty hepatic filter or through porto 
systemic collaterals. About 10 to 20% patients with ascites are prone to 
spontaneous bacterial peritonitis 
Spontaneous bacterial empyema in a pre - existing hydrothorax can also 
occur. Bacterial meningitis should be considered in the cirrhotics with febrile 
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coma.  In cirrhotic patients with unexplained pyrexia or deterioration, sepsis 
should always be suspected. Other infections common are pneumonia, 
lymphangitis, endocarditis. 
CIRRHOTIC CARDIOMYOPATHY 
Cardiac abnormalities in cirrhosis are mainly due to the toxic effect of 
alcohol on the heart. But cirrhosis per se can cause cardiac dysfunction. 
The presence of one or more of the following defines cirrhotic 
cardiomyopathy 
 systolic and/or diastolic dysfunction 
 baseline increased cardiac output but blunted ventricular response to 
stimuli 
 electrophysiological abnormalities including prolonged Q – T interval on 
electrocardiography and chronotropic incompetence . 
 absence of overt left ventricular failure at rest 
Overt cardiac failure may be precipitated by major stresses such as TIPS, 
liver transplantation or sepsis may .  
PATHOGENESIS 
 the  cardiomyocyte  β - adrenergic signalling pathway 
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  changes in the lipid composition causing decreased fluidity of the 
cardiomyocyte plasma membrane and the negative effects of substances 
such as nitric oxide, carbon monoxide and endo cannabinoids on heart 
muscle. 
The treatment of cirrhotic cardiomyopathy includes diuretics, long - term 
aldosterone antagonists and beta - blockers.  Avoid  vasodilators and digitalis.. 
Cardiac function is improved by liver transplantation.  
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MATERIALS AND METHODS 
SETTING : 
The study was conducted on 100 patients admitted in Government Rajaji 
Hospital & Madurai Medical College during the study period from March 2018 
to August  2018. 
INCLUSION CRITERIA 
All patients aged 18 years and above diagnosed to have cirrhosis of liver 
admitted in Medicine Department and Medical Gastroenterology department. 
EXCLUSION CRITERIA 
 Previous history of portal hypertensive bleeding, hepatocellular 
carcinoma, portal vein thrombosis. 
  Previous or current treatment with β blockers, diuretics or other 
vasoactive drugs.  
 Budd Chiari Syndrome and other causes of non-cirrhotic portal 
hypertension. 
ANTICIPATED OUTCOME: 
Increased right lobe of liver diameter to serum albumin ratio correlates 
with the severity of varices in cirrhosis patients. 
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DATA COLLECTION 
 After confirmation of diagnosis and explaining the purpose & procedure 
of study, written informed consent in Tamil will be obtained. The 
selected patients will be evaluated as per pro forma.  
 Serum urea and serum creatinine will be taken at the time of admission. 
Ultrasonography and renal doppler for measuring renal resistive index 
will be taken prior to coronary angiography. Serum urea and serum 
creatinine will be taken 24 hours and 48 hours post procedure 
                                  
DESIGN OF STUDY: Prospective analytical study. 
 
PERIOD OF STUDY: March 2018 to August 2018 
 
COLLABORATING DEPARTMENTS: 
Department of Biochemistry 
Department of Radiology 
Department of Medical gateroentrology 
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ETHICAL CLEARANCE: Approved 
 
CONSENT: Individual written and informed 
 
ANALYSIS:  STATISTICAL METHODS: 
The data collected during the study was formulated into a master chart in 
Microsoft office excel and statistical analysis was done with help of computer 
using statistical software package SPSS V.17 for windows. Using this software,  
frequencies, range, mean, standard deviation and ‘p‘were calculated through 
student ‘t’ test, one way ANOVA, pearson correlation and chi square test . 
 P value of < 0.05 was taken as significant. 
 
CONFLICT OF INTEREST: NIL 
 
FINANCIAL SUPPORT: NIL 
 
PARTICIPANTS: Patients of age>18yrs, admitted as in-patients at 
Govt.Rajaji hospital, Madurai who are diagnosed as cirrohosis. 
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OBSERVATION AND RESULTS 
 
TABLE 1: AGEWISE DISTRIBUTION 
AGE NUMBER OF CASES 
< 40 22 
40 – 50 42 
> 50 36 
Total 100 
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CHART 1: AGEWISE DISTRIBUTION 
 
 
 
 
Among 100, about 42% belong to the age group of 40 to 50. 
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TABLE 2: GENDER WISE DISTRIBUTION 
 
SEX NO OF CASES 
Male 90 
Female 10 
Total 100 
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 CHART 2: GENDER WISE DISTRIBUTION  
 
 
 
Among 100, there were 90 male and 10 females. 
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TABLE 3: DISTRIBUTION WITH RESPECT TO ETIOLOGY 
 
ETIOLOGY NO.OF CASES 
ALCOHOL 56 
AUTOIMMUNE 6 
CRYPTOGENIC 2 
VIRAL 32 
WILSON 4 
Total 100 
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CHART 3: DISTRIBUTION WITH RESPECT TO ETIOLOGY 
 
 
Alcoholism is the most common etiology contributing about 56% which 
is followed by viral 32% 
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TABLE 4: SERUM BILIRUBIN VALUES 
 
SR.BILIRUBIN NO OF CASES 
< 7 26 
 7 - 9 48 
> 9 26 
Total 100 
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CHART 4: SERUM BILIRUBIN VALUES 
 
 
 
The serum bilirubin values of most patients about 48% lie between 7-9 mg/dl. 
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TABLE 5: SERUM ALBUMIN VALUES 
ALBUMIN NO OF CASES 
< 3 30 
 3 - 4 38 
> 4 32 
Total 100 
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CHART 5: SERUM ALBUMIN VALUES 
 
 
 
Serum albumin levels of most of the patients about 38% fall between 3-4 g/dl. 
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TABLE 6: DISTRIBUTION BASED ON CHILD PUGH 
 
 
CHILD PUGH NO OF CASES 
A 30 
B 38 
C 32 
Total 100 
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CHART 6: DISTRIBUTION BASED ON CHILD PUGH 
 
 
 
About 38% fall under category B of Child Pugh classification 
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TABLE 7: DISTRIBUTION BASED ON RIGHT LOBE LIVER DIAMETER 
 
 
 
RIGHT LOBE OF LIVER NO OF CASES 
< 9 22 
 9 - 11 44 
 < 11 34 
Total 100 
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CHART 7: DISTRIBUTION BASED ON RIGHT LOBE LIVER 
DIAMETER 
 
 
The right lobe liver diameter of about 44% of patients fall between 9-11cm. 
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TABLE 8: RATIO (F/H) INTERPRETATION 
 
 
 
RATIO(F/H) NO OF CASES 
< 5 38 
 5 - 7 42 
 < 7 20 
Total 100 
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CHART 8: RATIO(F/H) INTERPRETATION 
 
 
 
The F/H ratio of about 42% of patients falls between 5-7. 
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TABLE 9: VARICEAL GRADE WISE DISTRIBUTION 
 
 
VARICEAL GRADE NO OF CASES 
0 21 
I 25 
II 40 
III 14 
Total 100 
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CHART 9: VARICEAL GRADE WISE DISTRIBUTION 
 
 
About 40% of the study population have been found to have grade 2 varices. 
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TABLE 10: VARICEAL GRADE VS RT LOBE LIVER DIAMETER 
 
 
 
VARICEAL GRADE VS RT LOBE LIVER 
variceal grade vs rt lobe liver Mean SD p' value 
0 10.54 1.15   
I 9.74 1.02   
II 10.32 1.22   
III 10.81 1.42 0.033 
  
P VALUE  Significant 
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CHART 10: VARICEAL GRADE VS RT LOBE LIVER 
 
For those with grade 3 varices when compared with right lobe liver 
diameter the standard deviation obtained is 1.42 which corresponds to a p value 
of 0.033 which is significant. It proves that there is direct correlation between 
right lobe liver diameter and oesophageal varices. 
 
9.2
9.4
9.6
9.8
10
10.2
10.4
10.6
10.8
11
0 I II III
10.54
9.74
10.32
10.81
VARICEAL GRADE VS RT LOBE LIVER
Mean
75 
 
TABLE 11: VARICEAL GRADE VS RATIO(F/H) 
 
VARICEAL GRADE VS RATIO(F/H) 
variceal grade vs Ratio (F/H) Mean SD p' value 
0 2.98 0.52   
I 5.14 0.59   
II 6.28 1.05   
III 7.96 1.34 <0.001 
  
  Significant 
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CHART 11: VARICEAL GRADE VS RATIO (F/H) 
 
 
For those with grade 3 varices when compared to F/H ratio with a mean 
value of 7.96 the standard deviation obtained is 1.34 which corresponds to the p 
value of  <0.001which is significant. 
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TABLE 12: VARICEAL GRADE VS BILIRUBIN 
VARICEAL GRADE VS BILIRUBIN 
variceal grade vs sr bilirubin Mean SD p' value 
0 7.35 2.27   
I 8.40 2.13   
II 8.45 1.86 0.164 
III 7.76 1.55 Not sig 
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CHART 12: VARICEAL GRADE VS BILIRUBIN 
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TABLE13: VARICEAL GRADE VS ALBUMIN 
 
VARICEAL GRADE VS ALBUMIN 
variceal grade vs albumin Mean SD p' value 
0 3.64 0.75   
I 3.54 0.93   
II 3.66 0.66 0.151 
III 3.1 0.98 Not sig 
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CHART 13: VARICEAL GRADE VS ALBUMIN 
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TABLE 14: CORRELATION BETWEEN VARICEAL GRADE VS RATIO 
(F/H) 
 
CORRELATION BETWEEN VARICEAL GRADE VS RATIO (F/H) 
variceal grade vs Ratio (F/H) Mean SD p' value 
0 2.98 0.52   
I 5.14 0.59   
II 6.28 1.05   
III 7.96 1.34 <0.001 
   
Significant 
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CHART 14:  CORRELATION  BETWEEN VARICEAL GRADE VS RATIO 
(F/H) 
 
 
The correlation coefficient is found to be 0.86 which is a good correlation. 
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DISCUSSION 
Among the study population of 100, about 42% belong to the age group 
of 40 to 50. Among 100, there were 90 male and 10 females. In this study , 
Alcoholism is the most common etiology contributing about 56% which is 
followed by viral 32%. The serum bilirubin values of most patients about 48% 
lie between 7-9 mg/dl . Serum albumin levels of most of the patients about 38% 
fall between 3-4 g/dl. About 38% fall under category B of Child Pugh 
classification. The right lobe liver diameter of about 44% of patients fall 
between 9-11cm. 
The F/H ratio of about 42% of patients falls within 5-7. About 40% of the 
study population have been found to have grade 2 varices. The standard 
deviation of  the study population of 42% whose values fall with within F/H 
ratio of 5-7 is found to be 1.36.  For those with grade 3 varices when compared 
with right lobe liver diameter the standard deviation obtained is 1.42 which 
corresponds to a p value of 0.033 which is significant. 
It proves that there is direct correlation between right lobe liver diameter 
and oesophageal varices. For those with grade 3 varices when compared to F/H 
ratio with a mean value of 7.96 the standard deviation obtained is 1.34 which 
corresponds to the p value of  <0.001which is significant. 
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The correlation coefficient is found to be 0.86 which is a good 
correlation. The right lobe liver diameter is a very easy parameter that can be 
measured simply as a part of ultrasound abdomen  and serum albumin levels are 
measured as routine biochemical investigation. 
Thus this method requires parameters which can be easily detected 
without any  additional efforts and thereby carries increased compliance. 
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CONCLUSION 
Higher grades of oesophageal varices was noted with higher right lobe of 
liver diameter to albumin ratios. Thus the Right lobe of liver to albumin ratio 
can be used as a screening tool to diagnose the presence of oesophageal varices. 
Hence, this can identify subset of patients who require prophylactic 
endoscopic management. Therefore, this reduces the economic burden on the 
patients and reduces the cost of management 
 
LIMITATIONS 
 It is a small scale study. 
 Long term follow up is not done. 
 Liver biopsy which is gold standard for diagnosis of cirrhosis has not 
been done. 
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PROFORMA  
Name: 
Age / Sex: 
Occupation: 
Presenting complaints: 
H/O jaundice 
H/O abdominal distension/pedal edema 
H/O hematochezia/melena/hematemesis 
H/O altered sensorium/altered sleep habit 
H/O fever 
H/O abdominal pain 
H/O oliguria/dysuria/hematuria 
Past History: 
H/o DM, HT, CKD, CVD, DRUG INTAKE, CAD, Thyroid 
disorders, CLD,renal transplantation and blood transfusion. 
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PERSONAL HISTORY: 
Alcohol intake/smoking/high risk behavior 
Clinical Examination: 
General Examination: 
Consciousness,  
Orientation to time,place,person 
Pallor,  
Jaundice,  
Clubbing,  
Lymphadenopathy,  
Hydration status 
Pedal edema 
Other signs of hepatocellular failure    
Vitals: 
 PR 
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 BP 
 RR 
 SpO2 
          Urine output 
Systemic examination: 
CVS: 
RS: 
ABDOMEN: 
           Presence of distended and dilated veins 
           Direction of flow 
           Free fluid 
           Hepatomegaly/splenomegaly 
CNS:               
   Laboratory investigations: 
a) Complete blood count, 
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b) Renal function test, 
c) Liver function test, 
d) PT-INR 
e) Serum albumin 
f) ultrasonography abdomen 
g) esophagoduodenoscopy 
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ABBREVIATIONS 
 
• RFT  -  RENAL FUNCTION TEST 
 
• AKI  - ACUTE KIDNEY INJURY 
 
• CLD  - CHRONIC LIVER DISESASE 
 
• CAD   - CORONARY ARTERY DISEASE 
 
• CCF  - CONGESTIVE CARDIAC FAILURE 
 
• Scr  - SERUM CREATININE 
 
• ECG   –  ELECTROCARDIOGRAM 
 
• LFT  - LIVER FUNCTION TEST 
 
• HRS  -  HEPATORENAL SYNDROME 
 
• MI   - MYOCARDIAL INFARCTION 
 
• RRI  -  RENAL RESISTIVE INDEX 
 
• HPS  - HEPATOPULMONARY SYNDROME 
 
• PPH  -  PORTO PULMONARY HYPERTENSION 

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CONSENT FORM 
ஆராய்சச்ி ஒப்புதல் படிவம் 
 
பபயர:்     தததி:  
வயது:     த ாயாளிஎண்:  
     ஆராய்சச்ிதசரக்்ககஎண்:  
  
இ ்தஆராய்சச்ியின்விவரங்களும்அதன்த ாக்கங்களும்முழுகம
யாகஎனக்குவிளக்கபட்டது.   
எனக்குவிளக்கபடட்விஷயங்ககள ான்புரி ்துபகாண்டுஎனதுமு
ழுமனதுடன்சம்மதிக்கிதேன்.  
இ ்தஆராய்சச்ியில்பிேரின் ிரப் ்தமின்றிஎன்பசா ்தவிருப்பத்
தின்தபரில்தான்பங்குபபறுகிதேன்மே்றும் ான்இ ்தஆராய்சச்ியில்இ
ரு ்துஎ ்தத ரமும்பின்வாங்கலாம்என்றும்அதனால்எ ்தபாதிப்பும்என
க்குஏே்படாதுஎன்பகதயும்புரி ்துபகாண்தடன்.  
 ான்என்னுகடயசுய ிகனவுடன்மே்றும்முழுசுத ்திரதத்ுடன்இ ்
தமருத்துவஆராய்சச்ியில்பங்குபகாள்ளசம்மதிக்கிதேன். 
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MASTER CHART 
S.No Age Sex Etiology 
Sr 
Bilirubin 
Albumin 
Child 
Pugh 
Rt 
Lobe 
Liver 
Ratio 
(F/H)   
Variceal 
Grade 
1 55 F VIRAL 7.4 4.4 A 11.1 3.3 0 
2 48 M ALCOHOL 8.2 3 B 12.1 4.5 II 
3 28 M ALCOHOL 3 2.3 C 11.5 3.6 0 
4 46 M ALCOHOL 5 3.3 A 10.1 4.3 I 
5 47 M ALCOHOL 8 2.4 C 11.2 5.5 III 
6 55 M ALCOHOL 9 2.5 B 12.5 6.5 I 
7 55 M VIRAL 11 2.2 C 9.7 7.6 III 
8 58 M ALCOHOL 13 2.3 A 9.8 4.6 I 
9 50 M ALCOHOL 9 3.3 B 9.9 3.4 0 
10 54 M ALCOHOL 4 2.5 C 8.9 5.5 I 
11 35 M VIRAL 8.5 3.1 A 10.7 6.6 II 
12 41 M VIRAL 7.4 2.5 C 11.8 9.9 III 
13 64 M VIRAL 7.9 2.6 B 10 7.7 II 
14 43 M ALCOHOL 8.6 2.6 B 9.8 6.6 II 
15 40 M ALCOHOL 8.3 4.4 A 8.9 5.5 I 
16 45 M ALCOHOL 7.4 3.3 C 12.3 4.5 I 
17 52 M ALCOHOL 6.5 2.8 A 9.7 8.8 III 
18 51 M VIRAL 5.5 3.7 B 9.5 7.8 II 
19 46 M ALCOHOL 8 2.9 A 9.9 3.4 0 
20 56 M VIRAL 9 3.9 C 8.9 7.7 II 
21 60 M ALCOHOL 12.8 3.8 B 12 6.6 II 
22 62 M ALCOHOL 4.5 3.7 A 11.1 2.4 0 
23 41 M ALCOHOL 6.9 4.4 B 12.1 5.5 II 
24 43 M VIRAL 7.8 4.6 C 9.8 3.6 0 
25 47 M VIRAL 8 4.7 A 9.9 4.5 I 
26 46 M ALCOHOL 7.7 4.4 B 10.9 6.6 II 
27 32 F AUTOIMMUNE 9.9 3.3 C 11.2 7.2 II 
28 21 F AUTOIMMUNE 10 4.4 A 8.8 5.6 I 
29 58 M ALCOHOL 10.8 3.4 B 9.1 2.3 0 
30 33 M ALCOHOL 9.4 4.7 C 9.8 5.5 I 
31 53 M CRYPTOGENIC 9.6 3.3 A 8.8 4.6 II 
32 44 M ALCOHOL 8.4 2.9 B 9.9 6.6 II 
33 50 M ALCOHOL 6.3 3.4 B 8.8 4.5 II 
34 39 M VIRAL 6.4 4.4 C 9.9 5.8 II 
35 35 F AUTOIMMUNE 10.5 3.9 B 8.8 5.5 II 
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36 55 M ALCOHOL 6.3 2.9 A 7.7 3.1 0 
37 46 M VIRAL 6.7 3.9 A 8.9 7.6 II 
38 34 M VIRAL 6.8 4.4 B 10.6 8.8 III 
39 26 M WILSON 7 4.7 C 12.6 7.4 III 
40 42 M VIRAL 6 4.4 A 11.6 5.5 II 
41 50 M ALCOHOL 9 3.8 C 12.1 6.6 II 
42 33 M WILSON 9.9 4.4 C 9.9 4.7 I 
43 50 M ALCOHOL 7.6 3.3 B 8.9 4.8 I 
44 50 M ALCOHOL 8.4 4 A 9.9 5.3 I 
45 39 M VIRAL 8 2.9 B 8.7 4.8 I 
46 53 M VIRAL 9.6 3.3 C 9.3 5.5 II 
47 59 M ALCOHOL 9.8 4.4 A 12.1 2.7 0 
48 44 M ALCOHOL 11.5 5.1 C 11.1 6.7 II 
49 58 M ALCOHOL 7.8 2.2 B 10.8 4.7 I 
50 55 F VIRAL 7.4 4.4 A 11.1 3.3 0 
51 46 M ALCOHOL 7.7 4.4 B 10.9 6.6 II 
52 32 F AUTOIMMUNE 9.9 3.3 C 11.2 7.2 II 
53 21 F AUTOIMMUNE 10 4.4 A 8.8 5.6 I 
54 58 M ALCOHOL 10.8 3.4 B 9.1 2.1 0 
55 33 M ALCOHOL 9.4 4.7 C 9.8 5.5 I 
56 53 M CRYPTOGENIC 9.6 3.3 A 8.8 4.6 II 
57 44 M ALCOHOL 8.4 2.9 B 9.9 6.6 II 
58 50 M ALCOHOL 6.3 3.4 B 8.8 4.5 II 
59 39 M VIRAL 6.4 4.4 C 9.9 5.8 II 
60 35 F AUTOIMMUNE 10.5 3.9 B 8.8 5.5 II 
61 55 M ALCOHOL 6.3 2.9 A 7.7 7.6 III 
62 46 M VIRAL 6.7 3.9 A 8.9 7.6 II 
63 34 M VIRAL 6.8 4.4 B 10.6 8.8 III 
64 26 M WILSON 7 4.7 C 12.6 7.4 III 
65 42 M VIRAL 6 4.4 A 11.6 5.5 II 
66 50 M ALCOHOL 9 3.8 C 12.1 6.6 II 
67 33 M WILSON 9.9 4.4 C 9.9 4.7 I 
68 50 M ALCOHOL 7.6 3.3 B 8.9 4.8 I 
69 50 M ALCOHOL 8.4 4 A 9.9 5.3 I 
70 39 M VIRAL 8 2.9 B 8.7 4.8 I 
71 53 M VIRAL 9.6 3.3 C 9.3 5.5 II 
72 59 M ALCOHOL 9.8 4.4 A 12.1 2.7 0 
73 44 M ALCOHOL 11.5 5.1 C 11.1 6.7 II 
74 58 M ALCOHOL 7.8 2.2 B 10.8 4.7 I 
75 55 F VIRAL 7.4 4.4 A 11.1 3.3 0 
76 55 F VIRAL 7.4 4.4 A 11.1 3.3 0 
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77 48 M ALCOHOL 8.2 3 B 12.1 4.5 II 
78 28 M ALCOHOL 3 2.3 C 11.5 3.6 0 
79 46 M ALCOHOL 5 3.3 A 10.1 2.6 0 
80 47 M ALCOHOL 8 2.4 C 11.2 5.5 III 
81 55 M ALCOHOL 9 2.5 B 12.5 7.8 III 
82 55 M VIRAL 11 2.2 C 9.7 7.6 III 
83 58 M ALCOHOL 13 2.3 A 9.8 4.6 I 
84 50 M ALCOHOL 9 3.3 B 9.9 3.4 0 
85 54 M ALCOHOL 4 2.5 C 8.9 5.5 I 
86 35 M VIRAL 8.5 3.1 A 10.7 6.6 II 
87 41 M VIRAL 7.4 2.5 C 11.8 9.9 III 
88 64 M VIRAL 7.9 2.6 B 10 7.7 II 
89 43 M ALCOHOL 8.6 2.6 B 9.8 6.6 II 
90 40 M ALCOHOL 8.3 4.4 A 8.9 5.5 I 
91 45 M ALCOHOL 7.4 3.3 C 12.3 2.1 0 
92 52 M ALCOHOL 6.5 2.8 A 9.7 8.8 III 
93 51 M VIRAL 5.5 3.7 B 9.5 7.8 II 
94 46 M ALCOHOL 8 2.9 A 9.9 3.4 0 
95 56 M VIRAL 9 3.9 C 8.9 7.7 II 
96 60 M ALCOHOL 12.8 3.8 B 12 6.6 II 
97 62 M ALCOHOL 4.5 3.7 A 11.1 2.8 0 
98 41 M ALCOHOL 6.9 4.4 B 12.1 5.5 II 
99 43 M VIRAL 7.8 4.6 C 9.8 6.6 I 
100 47 M VIRAL 8 4.7 A 9.9 2.3 0 
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